Why Almirall’s Klisyri quietly changes everyday sun-damaged skin care

Reviewed: ad hoc news B2B & Pro desk. Edited and checked on 2026-06-20, 07:02. Details in the imprint.

Klisyri is one of those tubes that do not look spectacular in the bathroom cabinet, yet for people with actinic keratosis the small Almirall ointment promises something big - a concentrated, five-day hit on rough, sun-damaged spots that many have carried around for years.

What Klisyri is meant to do

Actinic keratoses are those rough, scaly patches on sun-exposed skin that feel like sandpaper under your fingertips and can, over time, progress to non-melanoma skin cancer. Klisyri focuses exactly on these lesions on face and scalp with a short, intensive regimen.

The active substance tirbanibulin is a so-called microtubule inhibitor that disrupts cell division in abnormal keratinocytes and induces their death. In practice that means the cream is designed to selectively stress the damaged cells so that the skin can renew itself more cleanly over the following weeks.

How the five-day therapy feels

Patients apply a small, pea-sized amount of Klisyri once daily for five days to a limited field of up to 25 square centimeters. That is a surprisingly compact treatment window compared with some older field therapies, which often demand weeks of daily application.

Those five days are rarely comfortable. Many users experience burning, redness, scaling, sometimes even small crusts in the treated area. Still, for many it feels more manageable to grit their teeth through a clearly defined short course rather than a multi-week slog where the mirror reminds them every morning.

Strengths against older options

From a dermatologist’s point of view, the clear strength of Klisyri is this short, fixed treatment duration combined with targeted field therapy. In everyday practice, adherence tends to be higher when patients can literally mark the therapy days in the calendar and see an end in sight.

Compared with older creams for actinic keratosis that may require three or four weeks of use, the five-day schedule can fit more easily between holidays, important meetings, or family photos. That makes the therapy more compatible with real lives, not just with study protocols.

Where it still tests patience

The flip side is that the visible skin reaction often peaks after the last application, and the healing phase may stretch over several weeks. During that time, the treated area can look worse before it looks better, with intense redness and flaking.

Cosmetically that is a burden, especially when the field sits right on the forehead or nose. Makeup can cover some of it, but many patients still plan their Klisyri week for a quieter period, when they can accept a raw, irritated look in front of the mirror.

Who the therapy is for

Klisyri is prescribed for adults with non-hyperkeratotic, non-hypertrophic actinic keratoses on the face or scalp. In other words, for lesions that are still relatively flat and have not yet built a thick horny layer or pronounced elevation.

For very thick, isolated lesions, dermatologists may still prefer procedures like cryotherapy with liquid nitrogen or curettage. Many physicians see Klisyri rather as a field option when multiple rough spots cluster on a sun-damaged background, signalling chronic UV abuse.

Access and price point

Almirall markets Klisyri as a prescription medicine, with reimbursement conditions differing between countries. Patients usually receive a pack with individually sealed sachets or a small tube, depending on the market, to simplify the exact five-day dosing.

Prices can be noticeable for a small-looking amount of cream, which sometimes creates friction at the pharmacy counter. On the other hand, some health systems highlight that a short, effective field treatment may save follow-up costs compared with repeated procedures for progressing lesions.

Why Almirall cares about this tube

For Almirall, Klisyri is more than just another cream on the shelf. It underlines the company’s focus on medical dermatology, especially conditions that sit between cosmetic annoyance and serious disease, like actinic damage that can evolve into carcinoma.

Net-net, the product gives Almirall a specialized portfolio piece that can anchor deeper relationships with dermatology practices, where physicians appreciate therapies that fit realistically into their patients’ everyday routines while targeting a growing, UV-driven problem.

Company context and stock note

Klisyri fits into Almirall’s broader dermatology pipeline alongside treatments for atopic dermatitis, psoriasis, and other chronic skin diseases, and underscores the Spanish company’s strategy of focusing tightly on skin health. Shares of Almirall S.A. (ES0157097017) are listed in Madrid; current trading data should be checked on the respective exchange at the time of reading.

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.

en | ES0157097017 | ALMIRALL | boerse | 69587625 | bgmi